share_log

Castle Biosciences Announced The Publication Of Two Recent Studies That Provide Further Support For The Clinical Need Of Its MyPath Melanoma Gene Expression Profile Test Designed To Aid In Providing An Accurate Diagnosis For Ambiguous Melanocytic Lesions

Benzinga ·  Oct 16 19:12
Castle Biosciences Announced The Publication Of Two Recent Studies That Provide Further Support For The Clinical Need Of Its MyPath Melanoma Gene Expression Profile Test Designed To Aid In Providing An Accurate Diagnosis For Ambiguous Melanocytic Lesions
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment